SCHEMBL24766573

SCHEMBL24766573

OC[C@H]1C[C@H]1c1cc(Cl)cc(N2CCOCC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ RAF1 P04049 1/20 0.40
▸ BRAF P15056 1/20 0.40
▸ KMT2A Q03164 3/20 0.39
▸ PIK3CD O00329 2/20 0.39
▸ PIK3CB P42338 2/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ CNR2 P34972 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ TSHR P16473 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29434079 0.79 MAPT (0.41) MAPTCYP1A2CYP2D6RAF1BRAF
SCHEMBL29434081 0.79 MAPT (0.41) MAPTCYP1A2CYP2D6RAF1BRAF
SCHEMBL24766292 0.76 MAPT (0.49) MAPTCYP1A2CYP2D6KMT2APIK3CA
SCHEMBL17204101 0.75 MAPT (0.61) MAPTCYP1A2CYP2D6KMT2APIK3CB
SCHEMBL24766540 0.75 AKT1 (0.45) MAPTKMT2APIK3CARAB9AMEN1
SCHEMBL24766575 0.75 AKT1 (0.45) MAPTKMT2APIK3CARAB9AMEN1
SCHEMBL24766449 0.74 MAPT (0.47) MAPTCYP1A2CYP2D6RAF1BRAF
SCHEMBL24766046 0.74 CYP1A2 (0.49) MAPTCYP1A2CYP2D6RAF1BRAF
SCHEMBL913513 0.72 MAPT (0.44) MAPTCYP1A2CYP2D6RAF1BRAF
SCHEMBL23299977 0.71 MAPT (0.53) MAPTCYP1A2CYP2D6KMT2APIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11407737-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407737-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback